Norovirus vaccine formulations
The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
1. A composition comprising two or more Norovirus antigens and a mucoadhesive, wherein at least one of the Norovirus antigens is from genogroup I and at least one of the Norovirus antigens is from genogroup II, and wherein the amount of each of the two or more Norovirus antigens is from about 1 μg to about 100 μg per dose.
2. The composition of claim 1 , wherein the antigen comprises Norovirus virus-like particles (VLPs).
3. The composition of claim 2 , wherein the Norovirus VLPs comprise a capsid protein.
4. The composition of claim 3 , wherein the capsid protein is VP1 and/or VP2.
5. The composition of claim 2 , wherein the VLPs are monovalent VLPs.
6. The composition of claim 2 , wherein the VLPs are multivalent VLPs.
7. The composition of claim 1 , wherein the genogroup I is GI.1 and the genogroup II is GII.4.
8. The composition of claim 1 , wherein the mucoadhesive is selected from the group consisting of chitosan, chitosan salt, chitosan base, chitosan glutamate, polysaccharides, glycosaminoglycans, chondroitin sulfate, dermatan sulfate chondroitin, keratan sulfate, heparin, heparan sulfate, hyaluronan, pectin, alginate, glycogen, amylase, amylopectin, cellulose, chitin, stachyose, unulin, dextrin, dextran, cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrollidone, mucin, mucopolysaccharides, cellulose derivatives, hydroxypropyl methylcellulose, carboxymethylcellulose, lectins, fimbrial proteins, and deoxyribonucleic acid.
9. The composition of claim 8 , wherein the mucoadhesive is a polysaccharide.
10. The composition of claim 1 , further comprising an adjuvant.
11. The composition of claim 10 , wherein the adjuvant is selected from the group consisting of toll-like receptor (TLR) agonists, monophosphoryl lipid A (MPL), synthetic lipid A, lipid A mimetics or analogs, aluminum salts, cytokines, saponins, muramyl dipeptide (MDP) derivatives, CpG oligos, lipopolysaccharide (LPS) of gram-negative bacteria, polyphosphazenes, emulsions, virosomes, cochleates, poly(lactide-co-glycolides) (PLG) microparticles, poloxamer particles, microparticles, and liposomes.
12. The composition of claim 11 , wherein the adjuvant is a toll-like receptor (TLR) agonist.
13. The composition of claim 12 , wherein the adjuvant is MPL.
14. A method of generating antibodies to Norovirus antigens, comprising administering to a subject the composition of claim 1 .
15. The method of claim 14 , wherein the composition is administered to the subject by a route selected from the group consisting of mucosal, intranasal, sublingual, oral, rectal, vaginal, intramuscular, intravenous, subcutaneous, intradermal, subdermal, and transdermal routes of administration.
16. The method of claim 15 , wherein the route of administration is intramuscular.
17. The method of claim 15 , wherein the route of administration is intranasal.
18. The method of claim 17 , wherein the composition is administered using an inhaler.